|
LIRRH Trial for the Right-sided Colon Cancer
RECRUITINGN/ASponsored by Chaoxi Zhou
Actively Recruiting
PhaseN/A
SponsorChaoxi Zhou
Started2025-05-01
Est. completion2027-04-28
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07207317
Summary
The aim of this clinical trial is to compare the short- and long-term outcomes of laparoscopic ileocecal reconstruction right hemicolectomy (LIRRH) with those of traditional laparoscopic right hemicolectomy (TRH) for ascending and proximal transverse colon cancer.
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria: * Age 18-75 years * ASA physical status ≤ III * Endoscopy and biopsy-proven colon adenocarcinoma * Contrast-enhanced abdominal CT showing primary tumor located in the ascending colon or proximal transverse colon (proximal one-third) * Pre-operative clinical stage: TanyNanyM0 * Able to understand the study protocol, willing to participate, and provide written informed consent Exclusion Criteria: * History of hypertensive crisis or hypertensive encephalopathy. * Severe cardiopulmonary insufficiency or any other contraindication to surgery. * Uncorrectable electrolyte disturbances (e.g., potassium, calcium, magnesium). * Evidence of significant bleeding diathesis or high hemorrhagic risk: * Prior intracranial or intraspinal hemorrhage. * Tumor invading major vessels with obvious bleeding risk. * Thrombotic or embolic event within 6 months before study treatment, or significant vascular disease (e.g., surgical-repair aortic aneurysm). * Clinically relevant hemoptysis or tumor bleeding of any cause within 1 month before screening. * Therapeutic-dose anticoagulation within 2 weeks before study treatment (except low-molecular-weight heparin). * Antiplatelet therapy within 10 days before study treatment (e.g., aspirin \> 325 mg/day, clopidogrel \> 75 mg/day, dipyridamole, ticlopidine, cilostazol). * Active tuberculosis. * Any active autoimmune disease or history of autoimmune disease with expected recurrence (including but not limited to SLE, RA, autoimmune hepatitis, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyper- or hypothyroidism, asthma requiring bronchodilators). * Pre-operative evidence of synchronous multiple primary colorectal cancers or other conditions requiring additional bowel resection. * Pre-operative imaging or intra-operative findings showing: * Tumor infiltration into adjacent organs requiring multi-visceral resection; * Distant metastasis; * Unresectable (unable to achieve R0) disease. * Other malignancies within the past 5 years, or familial adenomatous polyposis; except cured carcinoma in situ of the cervix, basal-cell carcinoma, papillary thyroid carcinoma, or cutaneous squamous-cell carcinoma. * Intestinal obstruction, perforation, or bleeding requiring emergency surgery. * Patient unsuitable or unable to tolerate laparoscopic surgery. * Pregnant or lactating women. * History of psychiatric disorders precluding compliance. * Prior neoadjuvant therapy. * Multidisciplinary team (MDT) decision that the patient is not appropriate for the study. * Patient unable to understand the study conditions/objectives and refuses to give informed consent.
Conditions3
Ascending Colon CancerCancerProximal Transverse Colon Cancer
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorChaoxi Zhou
Started2025-05-01
Est. completion2027-04-28
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07207317